GC
TEVA icon

Gratus Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Gratus Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$12.4M Sell
760,289
-9,844
-1% -$152K 0.49% 59
2024
Q1 		$10.9M Buy
770,133
+1,845
+0.2% +$23.3K 0.5% 63
2023
Q4 		$8.02M Buy
768,288
+4,923
+0.6% +$46K 0.45% 70
2023
Q3 		$7.79M Buy
+763,365
New +$7.11M 0.53% 61

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gratus Capital's TEVA Position: Q2 2024 in Review

Gratus Capital reduced its Teva Pharmaceuticals (TEVA) stake by 1.3% in Q2 2024, selling an estimated $152K and leaving 760,289 shares worth $12.4M. The position accounts for 0.49% of the portfolio, ranked #59.

Gratus Capital first reported a position in TEVA in Q3 2023 and has held it in 4 quarters since. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Gratus Capital held 760,289 shares of Teva Pharmaceuticals worth $12.4M as of Q2 2024.
  • Gratus Capital sold 9,844 Teva Pharmaceuticals shares in Q2 2024, an estimated $152K.
  • Teva Pharmaceuticals made up 0.49% of Gratus Capital's portfolio in Q2 2024, its #59 holding.
  • Gratus Capital first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.